Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations Dec 6, 2024 11:06AM
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment D Oct 25, 2024 09:42AM
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical Oct 14, 2024 10:43AM
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs Sep 20, 2024 11:20AM
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones Sep 18, 2024 09:30AM


Sep 16, 2024 09:31AM Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment fo
Jul 26, 2024 09:30AM Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
Apr 16, 2024 11:01AM Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Mar 26, 2024 11:06AM Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
Mar 12, 2024 11:15AM Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study  
Mar 12, 2024 07:04AM Psyence Biomedical (PBM) Issues Shareholder Letter
Mar 12, 2024 07:00AM Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones
Mar 11, 2024 07:00AM Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division
Mar 6, 2024 07:00AM Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
Jan 25, 2024 05:17PM Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
Sep 7, 2022 08:00AM Brixton Metals Announces Pacific Bay Minerals Starts Drilling at the Atlin Goldfields Project
Jul 21, 2022 08:00AM Brixton Metals Receives Initial Payment from Pacific Bay Minerals Ltd with Respect to the Earn-In Agreement at its Atlin Goldfields Project